Metformin Flamingo Pharma Uk (Metformin Hydrochloride)

Metformin acts primarily by activating AMP‑activated protein kinase (AMPK), which suppresses hepatic gluconeogenesis, reduces intestinal glucose absorption, and enhances peripheral insulin sensitivity. These actions collectively lower fasting and post‑prandial blood glucose without increasing insulin secretion.

The exact dose is determined by the prescribing healthcare professional based on individual factors such as age, renal function, and glycemic targets. The prescriber will start with a low dose and titrate upward as needed to achieve optimal blood‑glucose control.

Safety data for metformin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin improves insulin sensitivity and does not stimulate insulin release, so it carries a lower risk of hypoglycemia compared with sulfonylureas, which increase insulin secretion. Metformin is also associated with modest weight loss, whereas sulfonylureas can cause weight gain.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from moisture and direct sunlight. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Metformin is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

The most serious adverse reaction is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, hypoxia, or excessive alcohol intake. Severe hypoglycemia may also occur when metformin is combined with insulin or sulfonylureas.

Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and in those with conditions that predispose to hypoxia such as severe heart failure or recent myocardial infarction.